Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells

Biochemical Pharmacology

Volumn 74, Issue 7, 2007, Pages 1029-1038

  Laïos, Ioanna ^a   Cleeren, Anny ^a   Leclercq, Guy ^a   Nonclercq, Denis ^b   Laurent, Guy ^b   Schlenk, Miriam ^c   Wellner, Anja ^c   Gust, Ronald ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

2,3 Bis(2 chloro 4 hydroxyphenyl) piperazines; 4,5 Bis(2 chloro 4 hydroxyphenyl) 2 imidazolines; Binding capacity; Down regulation; Estrogen receptor ; MCF 7 cells; Transactivation

Indexed keywords

4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ESTROGEN RECEPTOR ALPHA; IMIDAZOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN BINDING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 34548025388     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.045     Document Type: Article

References (32)

1. Alarid E.T. Lives and times of nuclear receptors. Mol Endocrinol 20 (2006) 1972-1981
2. Leclercq G., Lacroix M., Laïos I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr Cancer Drug Targets 6 (2006) 39-64
3. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
4. Nawaz Z., and O'Malley B.W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?. Mol Endocrinol 18 (2004) 493-499
5. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11 (2003) 695-707
6. McGuire W.L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5 (1978) 428-433
7. Borras M., Hardy L., Lempereur F., el Khissiin A.H., Legros N., Gol-Winkler R., et al. Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol 48 (1994) 325-336
8. Laïos I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., et al. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol 94 (2005) 347-359
9. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
10. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
11. Kong E.H., Pike A.C., and Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 31 (2003) 56-59
12. Kekenes-Huskey P.M., Muegge I., von Rauch M., Gust R., and Knapp E.W. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg Med Chem 12 (2004) 6527-6537
13. Jordan V.C., Schafer J.M., Levenson A.S., Liu H., Pease K.M., Simons L.A., et al. Molecular classification of estrogens. Cancer Res 61 (2001) 6619-6623
14. Gust R., Keilitz R., and Schmidt K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J Med Chem 44 (2001) 1963-1970
15. Gust R., Keilitz R., Schmidt K., and von Rauch M. (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode. J Med Chem 45 (2002) 3356-3365
16. Gust R., Keilitz R., and Schmidt K. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines. J Med Chem 45 (2002) 2325-2337
17. von Rauch M., Schlenk M., and Gust R. Effects of C2-alkylation, N-alkylation, and N,N′-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines. J Med Chem 47 (2004) 915-927
18. Soule H.D., Vazguez J., Long A., Albert S., and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51 (1973) 1409-1416
19. Levenson A.S., and Jordan V.C. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57 (1997) 3071-3078
20. Hafner F., Holler E., and von Angerer E. Effect of growth factors on estrogen receptor mediated gene expression. J Steroid Biochem Mol Biol 58 (1996) 385-393
21. Pons M., Gagne D., Nicolas J.C., and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9 (1990) 450-459
22. Tamrazi A., Carlson K.E., Rodriguez A.L., and Katzenellenbogen J.A. Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol Endocrinol 19 (2005) 1516-1528
23. El Khissiin A., Journe F., Laios I., Seo H.S., and Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids 65 (2000) 903-913
24. Seo H.S., DeNardo D.G., Jacquot Y., Laïos I., Vidal Salazar D., Rojas Zambrana C., et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat 99 (2006) 121-134
25. Gee A.C., Carlson K.E., Martini P.G., Katzenellenbogen B.S., and Katzenellenbogen J.A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol 13 (1999) 1912-1923
26. El khissiin A., and Leclercq G. Exchange of bound estrogens and antiestrogens in MCF-7 cells: evidence for ligand-induced stable configurations of the estrogen receptor. Steroids 63 (1998) 565-574
27. Fliss A.E., Benzeno S., Rao J., and Caplan A.J. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72 (2000) 223-230
28. Leclercq G., Legros N., and Piccart M.J. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. J Steroid Biochem Mol Biol 41 (1992) 545-552
29. Gallo D., Jacquemotte F., Cleeren A., Laios I., Hadiy S., Rowlands M.G., et al. Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol Cell Endocrinol 268 (2007) 37-49
30. Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laios I., Laurent G., et al. Molecular basis of agonistic activity of ERa17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor α ligand binding domain. Lett Drug Des Discov 4 (2007) 346-355
31. Jacquot Y., Laïos I., Cleeren A., Nonclercq D., Bermont L., Refouvelet B., et al. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells. Bioorg Med Chem 15 (2007) 2269-2282
32. Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5 (2000) 939-948